There are currently 188 clinical trials in Tulsa, Oklahoma looking for participants to engage in research studies. Trials are conducted at various facilities, including Oklahoma Cancer Specialists and Research Institute-Tulsa, Natalie Warren Bryant Cancer Center at St. Francis Hospital, GSK Investigational Site and Natalie Warren Bryant Cancer Center at Saint Francis. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Oklahoma Study of Native American Pain Risk III: Stress and Resilience
Recruiting
The goal of this observational study is to learn about the relationship between environmental structural racism and discrimination and chronic pain risk in Native American adults. The main questions it aims to answer are: 1. How does environmental structural racism and discrimination affect chronic pain-promoting mechanisms in Native Americans? 2. What psychosocial factors buffer the negative effects of environmental structural racism and discrimination on chronic pain-promoting mechanisms?
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2025
Locations: University of Oklahoma - Schusterman Center, Tulsa, Oklahoma
Conditions: Discrimination, Racial, Stress Physiology, Pain
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
Recruiting
This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
03/26/2025
Locations: Central States Research, LLC, Tulsa, Oklahoma
Conditions: Early Alzheimer's Disease
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
Recruiting
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often pr... Read More
Gender:
ALL
Ages:
Between 15 years and 40 years
Trial Updated:
03/18/2025
Locations: Natalie Warren Bryant Cancer Center at Saint Francis, Tulsa, Oklahoma
Conditions: B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like
Semaglutide Therapy for Alcohol Reduction - Tulsa
Recruiting
The purpose of this research study is to determine if semaglutide, when compared to placebo, is safe and may reduce alcohol drinking in individuals who endorse symptoms consistent with alcohol use disorder.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: OSU Biomedical Imaging Center, Tulsa, Oklahoma
Conditions: Alcohol Use Disorder
A Phase 1 Clinical Study of NXP800 in Subjects with Advanced Cancers and Expansion in Subjects with Ovarian Cancer
Recruiting
The purpose of the dose escalation phase is to evaluate the safety profile of escalating doses and dose schedules of NXP800. In the expansion phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be estimated.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Oklahoma Cancer Specialists and Research Institute, Tulsa, Oklahoma
Conditions: Advanced Solid Tumor, Ovarian Cancer, Ovarian Clear Cell Carcinoma, Ovarian Clear Cell Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Endometrioid Tumor, ARID1A Gene Mutation
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Recruiting
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: Cancer Treatment Centers of America, Tulsa, Oklahoma +1 locations
Conditions: Previously Treated Non-Small Cell Lung Cancer
A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)
Recruiting
The purpose of this study is to evaluate the efficacy and the safety of two doses of CHF6001 (Tanimilast) as add-on to maintenance triple therapy in the target patient population.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
03/11/2025
Locations: Chiesi Clinical Trial - Site 840692, Tulsa, Oklahoma
Conditions: Chronic Obstructive Pulmonary Disease
Post Market Clinical Follow-up (PMCF) Study of Clareon Vivity & Clareon PanOptix
Recruiting
The purpose of this Post-Market Clinical Follow-up study is to describe the long-term safety and performance of the Clareon Vivity and Vivity Toric and Clareon PanOptix and PanOptix Toric IOLs.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: Tulsa Ophthalmology, Tulsa, Oklahoma
Conditions: Aphakia, Astigmatism, Presbyopia
Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder
Recruiting
The study's purpose is to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in subjects with Obsessive Compulsive Disorder (OCD)
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/07/2025
Locations: Central States Research, LLC, Tulsa, Oklahoma
Conditions: Obsessive-Compulsive Disorder
ANTIVIRAL TREATMENT OF CYTOMEGALOVIRUS IN DEPRESSION
Recruiting
This study aims to determine whether treatment of CMV positive (CMV+) individuals with major depressive disorder (MDD) with valganciclovir (VGCV) alters neural circuitry, reduces inflammation, and improves depressive behavior and symptoms to a greater extent than placebo. In this double-blind, randomized placebo-controlled, parallel group trial, 24 individuals with a Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR) scale score ≥ 14 will be enrolled to participate in an 8-week t... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/03/2025
Locations: Laureate Institute for Brain Research, Tulsa, Oklahoma
Conditions: Major Depressive Disorder
Neural Response to Inflammatory Challenge in Major Depressive Disorder
Recruiting
This is a parallel group, double-blinded, placebo-controlled study. Participants with MDD (n=90) and HC (n=90) will be randomly assigned (2:1) to receive either lipopolysaccharide (LPS) (0.8ng/kg of body weight) or placebo (same volume of 0.9% saline) administered as an intravenous bolus. This will yield the following groups: MDD-LPS (n=60), MDD-Placebo (n=30), HC-LPS (n=60), HC-placebo (n=30). There are three main aims: to identify immune pathways and neural circuits that respond differently t... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/03/2025
Locations: Laureate Institute for Brain Research, Tulsa, Oklahoma
Conditions: Major Depressive Disorder
Evaluation of a Keto-Like Supplement on Brain Responses to Emotional Stimuli in Depression
Recruiting
This study aims to determine whether a keto-like supplement relative to placebo results in functional brain changes during fMRI tasks evaluating positive and negative valence in individuals with moderate to severe depression. In this double-blind randomized placebo-controlled trial, 75 individuals with a Patient Health Questionnaire (PHQ-9) scale score ≥ 10 (MDD) will be enrolled to participate in an 8-week treatment study to obtain 60 completers. Participants will be randomized with a 1-1 ratio... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/03/2025
Locations: Laureate Institute for Brain Research, Tulsa, Oklahoma
Conditions: Depression